Article Figures & Data
Tables
Fibrinolytic Agent Recanalization n None Partial Complete rtPA 18 (21%) 13 (15%) 55 (64%) 86 Urokinase 10 (18%) 19 (33%) 28 (49%) 57 Note:—rtPA indicates recombinant tissue plasminogen activator.
Fibrinolytic Agent n(%) Urokinase (n = 57) 12 (21%) rtPA (n = 86) 31 (36%) Dosage <80 mg (n = 43) 11 (26%) Dosage ≥80 mg (n = 43) 20 (46%) Note:—rtPA indicates recombinant tissue plasminogen activator.
- Table 3:
Relationship between intracranial bleeding (hemorrhagic transformation and primary intracerebral hematoma) and neurologic outcome
Modified Rankin Scale Score n (%) n 0–2 3–4 5–6 Bleeding 1 (2%) 9 (21%) 33 (77%) 43 No bleeding 37 (37%) 33 (33%) 30 (30%) 100 Incidence of All Ischemic Lesions n (%) Incidence of Large Ischemic Lesions n (%) Occipital lobe 59 (41%) 11 (8%) Thalamus 54 (38%) 8 (6%) Mesencephalon 55 (39%) 33 (23%) Pons and medulla oblongata 95 (66%) 51 (36%) Territory of the SCA 63 (44%) 23 (16%) Territory of the AICA & PICA 62 (43%) 22 (15%) Note:—SCA indicates superior cerebellar artery; AICA, anterior inferior cerebellar artery; PICA, posterior inferior cerebellar artery.
In this issue
Jump to section
Related Articles
Cited By...
- Endovascular therapy for acute basilar artery occlusion: a review of the literature
- Three-Month and Long-Term Outcomes and Their Predictors in Acute Basilar Artery Occlusion Treated With Intra-Arterial Thrombolysis
- Glasgow Coma Scale Does Not Predict Outcome Post-Intra-Arterial Treatment for Basilar Artery Thrombosis
- Predictors of Subarachnoid Hemorrhage in Acute Ischemic Stroke With Endovascular Therapy
- Mechanical Thromboembolectomy for Acute Ischemic Stroke: Comparison of the Catch Thromboectomy Device and the Merci Retriever In Vivo
- Randomized Trial of Intraarterial Infusion of Urokinase Within 6 Hours of Middle Cerebral Artery Stroke: The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan